By Leveraging Data-driven Solutions, Co-development Opportunities, and Assay Innovation, Clients Can Experience Enhanced Product Performance, Cost-effectiveness, and Improved Decision-making Capabilities
The global oncology diagnostics in IVD market is expected to witness significant growth, driven by an increase in cancer incidence, technological developments in diagnostic tests, the growing number of screening tests, and supportive government initiatives. Owing to the intense competition in the market, the most prominent companies are investing heavily in research and development to create new diagnostic tests.
Personalized medicine, a fast-growing industry, seeks to tailor cancer treatment to the individual needs of each patient. This improvement is aided by the development of new diagnostic technologies capable of identifying genetic abnormalities that cause cancer progression. Oncology diagnostics mainly relies on genomic profiling, which allows the detection of precise mutations and variations in cancer-related genes. Healthcare professionals can personalize treatment strategies by analyzing genetic data, resulting in improved treatment outcomes and the capacity to predict cancer patient prognosis.
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- Genomic Health
- Guardant Health
- Illumina
- Invitae Corporation
- Myriad Genetics
- Natera
- PerkinElmer
- QIAGEN
- Roche Diagnostics
